aaps pharmscitech

The Journal of surgical research

[1] Tablet Formulation of a Polymeric Solid Dispersion Containing Amorphous Alkalinized Telmisartan.

[2] Intraperitoneal Administration of Telmisartan Prevents Postsurgical Adhesion Band Formation.

[3] telmisartan and cardioprotection

[4] assessment of serum lipid metabolism index and cytokine levels in patients with type 2 diabetes mellitus complicated by coronary heart disease after telmisartan combined with lipid-lowering drug treatment

[5] combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model

[6] pharmacokinetic and bioequivalence study of a telmisartan/s-amlodipine fixed-dose combination (ckd-828) formulation and coadministered telmisartan and s-amlodipine in healthy subjects

[7] Efficacy and tolerability of a single-pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg according to age, gender, race, hypertension severity, and previous antihypertensive use: planned analyses of a randomized trial

[8] Clinical utility of fixed-combination telmisartan–amlodipine in the treatment of hypertension

[9] Impact of telmisartan in modifying vascular risk

[10] Critical appraisal and pooled analysis of telmisartan alone or in combination with hydrochlorothiazide for achieving blood pressure goals

[11] Efficacy and tolerability of a single-pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg according to age, gender, race, hypertension severity, and previous antihypertensive use: planned analyses of a randomized trial

[12] Clinical utility of fixed-combination telmisartan–amlodipine in the treatment of hypertension

[13] Impact of telmisartan in modifying vascular risk

[14] Critical appraisal and pooled analysis of telmisartan alone or in combination with hydrochlorothiazide for achieving blood pressure goals

[15] Effects of telmisartan and candesartan on the metabolism of lipids and glucose in kidney transplant patients: A prospective, randomized crossover study

[16] A Meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension

[17] Internalization of Constitutively Active N111G Mutant of AT1 Receptor Induced by Angiotensin II–Receptor Antagonists Candesartan, Losartan, and Telmisartan: Comparison With Valsartan

[18] Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive rats

[19] Optimization of self-microemulsifying drug delivery system for phospholipid complex of telmisartan using D-optimal mixture design.

[20] Tablet Formulation of a Polymeric Solid Dispersion Containing Amorphous Alkalinized Telmisartan.

[21] ROLE OF CHITOSAN, CARBOXY METHYL CELLULOS, POLYVINYL PYRROLIDONE, KYRON T134 AND PRIMOGEL TO DESIGN THE MOUTH DISINTEGRATING TELMISARTAN TABLET WITH EXTENDED RELEASE PROFILE

[22] Intraperitoneal Administration of Telmisartan Prevents Postsurgical Adhesion Band Formation.

[23] cardiometabolic properties of telmisartan: new perspectives for use

[24] telmisartan and cardioprotection

[25] efficacy of telmisartan plus amlodipine in nonresponders to ccb monotherapy

[26] assessment of serum lipid metabolism index and cytokine levels in patients with type 2 diabetes mellitus complicated by coronary heart disease after telmisartan combined with lipid-lowering drug treatment

[27] severe angioedema of laryngeal inlet in a woman receiving telmisartan therapy undergoing breast conservation surgery

[28] combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model

[29] prevalence of diabetic nephropathy in type 2 diabetes mellitus in rural communities of guanajuato, mexico. effect after 6 months of telmisartan treatment

[30] pharmacokinetic and bioequivalence study of a telmisartan/s-amlodipine fixed-dose combination (ckd-828) formulation and coadministered telmisartan and s-amlodipine in healthy subjects